Non-viral b cell engineering methods
AssigneeRegents of the University of Minnesota
InventorsBranden S. Moriarity, Kanut Laoharawee, Beau R. Webber, Evan Kleinboehl
Life of this patent
Estimating the term…
Abstract
The present disclosure relates, in general, to non-viral methods for generating engineered B cell, and use of such B cells as cell-based therapeutics to treat disease.
Claims43
A method for genome engineering a B cell or a population of B cells to overexpress a gene of interest comprising introducing into the B cell or B cell population a plasmid, nanoplasmid or mini-circle comprising an expression cassette comprising a homology arm (HA), a polynucleotide encoding a gene of interest, a splice acceptor site, a promoter and a targeting site for a nuclease dependent cleavage system targeting molecule,
- wherein the expression cassette is inserted at a locus targeted by the targeting molecule.
A method for genome engineering a B cell or a population of B cells to overexpress an endogenous gene comprising introducing into the B cell or B cell population a plasmid, nanoplasmid or mini-circle comprising an expression cassette comprising a homology arm(s) (HA), a splice acceptor site, a promoter and a targeting site for a nuclease dependent cleavage system targeting molecule,
- wherein the expression cassette is inserted upstream of a target gene to be overexpressed.
The method of any one of the preceding claims, further comprising introducing into the B cell or B cell population a polynucleotide encoding a biomarker molecule useful to enrich for the B cell or a population of B cells.
The method of any one of the preceding claims, wherein the gene of interest integrates into the B cell genome via homology directed repair (HDR), homology-mediated end joining (HMEJ) or a combination of HDR/HMEJ.
The method of any one of the preceding claims, wherein the introduction of the plasmid or nanoplasmid is by transfection or electroporation.
The method of any one of the preceding claims, wherein efficiency of introduction is greater than 15%.
The method of any one of the preceding claims, wherein the B cell population has a viability of greater than 60% after 3 days.
The method of any one of the preceding claims, wherein the B cell or population of B cells is a primary B cell, a plasma cell, a mature B cell, a B cell line, naïve B cell, memory B cells, or plasma blast.
The method of any one of the preceding claims, wherein the plasmid or nanoplasmid comprises the promoter next to or near the gene of interest.
The method of any one of the preceding claims, wherein the gene of interest is a therapeutic gene or encodes a therapeutic protein.
The method of any one of the preceding claims, wherein the gene of interest is a donor polynucleotide that corrects a mutated genotype in a subject.
The method of any one of the preceding claims, wherein the plasmid or nanoplasmid further comprises a polynucleotide encoding a B cell receptor or fragment thereof.
A method of making a gene edited B cell or population of B cells, comprising:
- i) contacting a B cell or population of B cells with a plasmid, nanoplasmid or mini-circle comprising an expression cassette comprising a homology arm (HA), a splice acceptor site, a promoter and a targeting site for a nuclease dependent cleavage system targeting molecule, and optionally comprising a polynucleotide encoding a gene of interest;
- ii) culturing the B cell or population of B cells of i) in a media that promotes expansion of B cells;
- iii) isolating the B cell or population of B cells of ii) based on identification of a marker expressed only on a B cell or population of B cells carrying the plasmid or nanoplasmid;
- iv) culturing the isolated cells of iii) in a culture medium to expand the isolated cells expressing the gene of interest.
A gene edited B cell comprising
- i) a heterologous polynucleotide sequence encoding a gene of interest integrated in the B cell genome at a target location mediated by a nuclease dependent cleavage system, wherein the heterologous polynucleotide sequence is also flanked by portions of a homology arm and expressed via an endogenous promoter;
- and
- ii) a heterologous biomarker molecule.
Dependencies are inferred from the claim text.